RNAZ News & Events

TransCode Therapeutics has entered into an agreement with an institutional healthcare investor for financing of up to $20M. The arrangement comprises pre-paid advances of up to $6M and a three-year Standby Equity Purchase Agreement , or SEPA, providing the company the right to sell up to $14M of its common stock to the investor, subject to certain conditions. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138. In the company's Phase 1a clinical trial, TTX-MC138 met its safety endpoint and was well tolerated by patients. A Phase 2a clinical trial with TTX-MC138 is expected to begin in Q2. The pre-paid advance will be evidenced by convertible promissory notes priced at 95% of face value. TransCode will issue a $1M principal amount note concurrently with its Annual Report for 2025, and, subject to certain closing conditions, will issue an additional $5M principal amount note upon shareholder approval of the transaction. The advance will accrue interest at a simple annual rate of 5% and may be converted into TransCode's common stock.

TransCode Therapeutics announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics. TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by Unleash to the Unleash drug candidates together with the acquisition of all rights to the drug candidates owned by Unleash. Under the terms of the exclusive license agreement, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock of TransCode, convertible into an equal number of shares of common stock of TransCode. The Preferred Stock represents 6.8% of TransCode's common stock on a fully diluted basis assuming conversion of all TransCode preferred stock outstanding.

TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced the submission to the U.S. FDA of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first expansion into colorectal cancer.

TransCode Therapeutics announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme. The article was published in the peer-reviewed Journal of Functional Biomaterials. The study, entitled "Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models," resulted from a collaboration between TransCode and Michigan State University. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean for Research Development at the College of Human Medicine at Michigan State University and scientific co-founder of TransCode. The study demonstrated delivery of TTX-MC138 to human GBM tumors implanted into the brains of murine models after intravenous injection, resulting in sustained target engagement within the tumor. TTX-MC138 also induced apoptotic activity in tumors by five-fold, consistent with observed induction of tumor cell death. Importantly, treatment with TTX-MC138 resulted in a statistically significant increase in survival.